Regulatory & Policy

ARTHEx Biotech Secures FDA Fast Track Designation for ATX-01 in Myotonic Dystrophy Type 1

Edited by Robert McTiernan··3 min read

ARTHEx Biotech, a clinical-stage biotechnology company headquartered in Valencia, Spain, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ATX-01, an investigational RNA therapeutic, for the treatment of Myotonic Dystrophy Type 1 (DM1). ARTHEx Biotech is a privately held company with no publicly listed ticker symbol. ATX-01 is an antisense oligonucleotide designed to inhibit microRNA-23b (miR-23b), a natural suppressor of muscleblind-like (MBNL) protein expression. The drug was developed in-house, originating from research conducted by co-founder Rubén Artero at the University of Valencia. ATX-01 had previously received Orphan Drug Designation from the European Medicines Agency (EMA) for DM1.

Fast Track Designation allows more frequent interactions with the FDA during drug development, eligibility for rolling submission of marketing application sections, and potential qualification for Priority Review. These procedural mechanisms are reserved for therapies targeting conditions classified as serious or life-threatening where unmet medical need exists.

ATX-01 operates through a dual mechanism. In DM1, two processes deplete functional MBNL protein: miR-23b upregulation suppresses MBNL translation, while expanded toxic DMPK mRNA sequesters MBNL proteins in nuclear foci. The resulting loss of available MBNL drives widespread RNA mis-splicing across skeletal muscle, cardiac, and central nervous system tissues. By inhibiting miR-23b, ATX-01 both increases MBNL production and reduces toxic DMPK mRNA foci, restoring splicing patterns in animal models. The company's proprietary BOOST-ON platform pairs selective oligonucleotides with tissue delivery systems targeting skeletal muscle, heart, and brain. ARTHEx is currently evaluating ATX-01 in the Phase I/IIa ArthemiR study (NCT06300307), a multi-center, randomized, placebo-controlled trial enrolling an estimated 56 participants with genetically confirmed DM1. The primary endpoint is incidence of adverse events, with secondary measures including change in ankle dorsiflexion strength and pharmacokinetic parameters. Trial sites span France, the United States, and Italy.

Research context

The AllSci BriefSystematic R&D and deal news. Daily.

DM1 is the most common form of adult-onset muscular dystrophy, with disease onset typically occurring during adolescence and a clinical course marked by progressive disability and reduced life expectancy. No disease-modifying therapy has received FDA or EMA approval for DM1. Current management remains limited to symptomatic treatment. Reviews of the DM1 drug development pipeline published in 2022 and in a subsequent market-facing analysis confirm that while several candidates have entered clinical testing, none has advanced to regulatory approval.

The competitive landscape for DM1 therapies includes multiple modalities. Most programs in development target the toxic CUG-repeat RNA produced by the expanded DMPK gene, using antisense oligonucleotides or small molecules to degrade or neutralize the aberrant transcript. ARTHEx's approach differs from these direct DMPK-targeting strategies. Rather than acting on the toxic RNA itself, ATX-01 targets a regulatory microRNA upstream of MBNL translation, aiming to increase the pool of free MBNL protein through a complementary pathway. This distinction means ATX-01 addresses MBNL depletion both by boosting protein synthesis and by reducing sequestration, whereas competitors that solely degrade toxic DMPK mRNA address only the sequestration component. Whether this dual mechanism translates into a clinical differentiation remains to be established through trial data.

The Fast Track Designation follows a period of increased regulatory attention to neuromuscular diseases, though no novel approvals for DM1 appeared in recent FDA and EMA approval summaries covering Q2 2024 through Q1 2025. ATX-01's Phase I/IIa trial is designed to generate safety and early efficacy data, and the designation may facilitate iterative regulatory dialogue as those results emerge.

Spot something wrong? Report an issue with this article